The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation

Philip Jay Bierman, J. C. Lynch, Robert G Bociek, V. L. Whalen, A. Kessinger, Julie Marie Vose, James Olen Armitage

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Background: The International Prognostic Factors Project on Advanced Hodgkin's Disease developed a seven-factor prognostic score consisting of serum albumin, hemoglobin, gender, stage, age, leukocytosis and lymphocytopenia for newly diagnosed Hodgkin's disease patients who receive chemotherapy. The purpose of this study was to determine whether this prognostic score would also be useful for Hodgkin's disease patients undergoing autologous hematopoietic stem cell transplantation. Patients and methods: We performed a retrospective review of 379 patients who had autologous transplants for Hodgkin's disease, at the University of Nebraska Medical Center between October 1984 and December 1999. Multivariate analysis was performed to determine whether the prognostic factors identified by the International Prognostic Factors Project adversely influenced event-free survival (EFS) or overall survival (OS). Results: Low serum albumin, anemia, age and lymphocytopenia were associated with poorer EFS and OS. Gender, stage and leukocytosis were not associated with significantly poorer outcomes. Estimated 10-year EFS was 38%, 23% and 7% for patients with 0-1, 2-3 or ≥4 of the adverse prognostic characteristics identified by the International Prognostic Factors Project, respectively. Conclusions: The prognostic score for advanced disease is also useful for relapsed and refractory Hodgkin's disease patients undergoing high-dose therapy followed by autologous hematopoietic stem cell transplantation.

Original languageEnglish (US)
Pages (from-to)1370-1377
Number of pages8
JournalAnnals of Oncology
Volume13
Issue number9
DOIs
StatePublished - Sep 1 2002

Fingerprint

Hematopoietic Stem Cell Transplantation
Hodgkin Disease
Disease-Free Survival
Lymphopenia
Leukocytosis
Serum Albumin
Survival
Autografts
Anemia
Hemoglobins
Multivariate Analysis
Drug Therapy

Keywords

  • Autologous transplantation
  • Hodgkin's disease
  • Prognostic factors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{7f701cddd7a24956b79dd8bbd6ac31b4,
title = "The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation",
abstract = "Background: The International Prognostic Factors Project on Advanced Hodgkin's Disease developed a seven-factor prognostic score consisting of serum albumin, hemoglobin, gender, stage, age, leukocytosis and lymphocytopenia for newly diagnosed Hodgkin's disease patients who receive chemotherapy. The purpose of this study was to determine whether this prognostic score would also be useful for Hodgkin's disease patients undergoing autologous hematopoietic stem cell transplantation. Patients and methods: We performed a retrospective review of 379 patients who had autologous transplants for Hodgkin's disease, at the University of Nebraska Medical Center between October 1984 and December 1999. Multivariate analysis was performed to determine whether the prognostic factors identified by the International Prognostic Factors Project adversely influenced event-free survival (EFS) or overall survival (OS). Results: Low serum albumin, anemia, age and lymphocytopenia were associated with poorer EFS and OS. Gender, stage and leukocytosis were not associated with significantly poorer outcomes. Estimated 10-year EFS was 38{\%}, 23{\%} and 7{\%} for patients with 0-1, 2-3 or ≥4 of the adverse prognostic characteristics identified by the International Prognostic Factors Project, respectively. Conclusions: The prognostic score for advanced disease is also useful for relapsed and refractory Hodgkin's disease patients undergoing high-dose therapy followed by autologous hematopoietic stem cell transplantation.",
keywords = "Autologous transplantation, Hodgkin's disease, Prognostic factors",
author = "Bierman, {Philip Jay} and Lynch, {J. C.} and Bociek, {Robert G} and Whalen, {V. L.} and A. Kessinger and Vose, {Julie Marie} and Armitage, {James Olen}",
year = "2002",
month = "9",
day = "1",
doi = "10.1093/annonc/mdf228",
language = "English (US)",
volume = "13",
pages = "1370--1377",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation

AU - Bierman, Philip Jay

AU - Lynch, J. C.

AU - Bociek, Robert G

AU - Whalen, V. L.

AU - Kessinger, A.

AU - Vose, Julie Marie

AU - Armitage, James Olen

PY - 2002/9/1

Y1 - 2002/9/1

N2 - Background: The International Prognostic Factors Project on Advanced Hodgkin's Disease developed a seven-factor prognostic score consisting of serum albumin, hemoglobin, gender, stage, age, leukocytosis and lymphocytopenia for newly diagnosed Hodgkin's disease patients who receive chemotherapy. The purpose of this study was to determine whether this prognostic score would also be useful for Hodgkin's disease patients undergoing autologous hematopoietic stem cell transplantation. Patients and methods: We performed a retrospective review of 379 patients who had autologous transplants for Hodgkin's disease, at the University of Nebraska Medical Center between October 1984 and December 1999. Multivariate analysis was performed to determine whether the prognostic factors identified by the International Prognostic Factors Project adversely influenced event-free survival (EFS) or overall survival (OS). Results: Low serum albumin, anemia, age and lymphocytopenia were associated with poorer EFS and OS. Gender, stage and leukocytosis were not associated with significantly poorer outcomes. Estimated 10-year EFS was 38%, 23% and 7% for patients with 0-1, 2-3 or ≥4 of the adverse prognostic characteristics identified by the International Prognostic Factors Project, respectively. Conclusions: The prognostic score for advanced disease is also useful for relapsed and refractory Hodgkin's disease patients undergoing high-dose therapy followed by autologous hematopoietic stem cell transplantation.

AB - Background: The International Prognostic Factors Project on Advanced Hodgkin's Disease developed a seven-factor prognostic score consisting of serum albumin, hemoglobin, gender, stage, age, leukocytosis and lymphocytopenia for newly diagnosed Hodgkin's disease patients who receive chemotherapy. The purpose of this study was to determine whether this prognostic score would also be useful for Hodgkin's disease patients undergoing autologous hematopoietic stem cell transplantation. Patients and methods: We performed a retrospective review of 379 patients who had autologous transplants for Hodgkin's disease, at the University of Nebraska Medical Center between October 1984 and December 1999. Multivariate analysis was performed to determine whether the prognostic factors identified by the International Prognostic Factors Project adversely influenced event-free survival (EFS) or overall survival (OS). Results: Low serum albumin, anemia, age and lymphocytopenia were associated with poorer EFS and OS. Gender, stage and leukocytosis were not associated with significantly poorer outcomes. Estimated 10-year EFS was 38%, 23% and 7% for patients with 0-1, 2-3 or ≥4 of the adverse prognostic characteristics identified by the International Prognostic Factors Project, respectively. Conclusions: The prognostic score for advanced disease is also useful for relapsed and refractory Hodgkin's disease patients undergoing high-dose therapy followed by autologous hematopoietic stem cell transplantation.

KW - Autologous transplantation

KW - Hodgkin's disease

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=0036737680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036737680&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdf228

DO - 10.1093/annonc/mdf228

M3 - Article

VL - 13

SP - 1370

EP - 1377

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -